Study summary
A 4-month antibody course kept more people off treatment failure
54%free of treatment failure at 12 months (9 mg), vs 30%
What was tested
Ianalumab, an antibody that depletes B cells and blocks the BAFF receptor, given monthly for 4 months, with eltrombopag, against placebo plus eltrombopag, after first-line steroids failed.
What they found
- At 12 months, 54% (9 mg) and 51% (3 mg) were free of treatment failure vs 30% with placebo.
- Stable response at 6 months: 62% vs 39%.
- Serious side effects were more common at 9 mg (16% vs 4%).
What it means
Could offer a short course instead of indefinite treatment.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.